Cargando…

Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma

BACKGROUND: The literature regarding esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy (IMRT) for esophageal squamous cell carcinoma (ESCC) remains lacking. We aimed to investigate the risk factors of esophageal fistula among ESCC patients undergoing de...

Descripción completa

Detalles Bibliográficos
Autores principales: Pao, Tzu-Hui, Chen, Ying-Yuan, Chang, Wei-Lun, Chang, Jeffrey Shu-Ming, Chiang, Nai-Jung, Lin, Chia-Ying, Lai, Wu-Wei, Tseng, Yau-Lin, Yen, Yi-Ting, Chung, Ta-Jung, Lin, Forn-Chia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121322/
https://www.ncbi.nlm.nih.gov/pubmed/33989365
http://dx.doi.org/10.1371/journal.pone.0251811
_version_ 1783692315074756608
author Pao, Tzu-Hui
Chen, Ying-Yuan
Chang, Wei-Lun
Chang, Jeffrey Shu-Ming
Chiang, Nai-Jung
Lin, Chia-Ying
Lai, Wu-Wei
Tseng, Yau-Lin
Yen, Yi-Ting
Chung, Ta-Jung
Lin, Forn-Chia
author_facet Pao, Tzu-Hui
Chen, Ying-Yuan
Chang, Wei-Lun
Chang, Jeffrey Shu-Ming
Chiang, Nai-Jung
Lin, Chia-Ying
Lai, Wu-Wei
Tseng, Yau-Lin
Yen, Yi-Ting
Chung, Ta-Jung
Lin, Forn-Chia
author_sort Pao, Tzu-Hui
collection PubMed
description BACKGROUND: The literature regarding esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy (IMRT) for esophageal squamous cell carcinoma (ESCC) remains lacking. We aimed to investigate the risk factors of esophageal fistula among ESCC patients undergoing definitive concurrent chemoradiotherapy (CCRT) via IMRT technique. METHODS: A total of 129 consecutive ESCC patients receiving definitive CCRT with IMRT between 2008 and 2018 were reviewed. The cumulative incidence of esophageal fistula and survival of patients were estimated by the Kaplan–Meier method and compared between groups by the log-rank test. The risk factors of esophageal fistula were determined with multivariate Cox proportional hazards regression analysis. RESULTS: Median follow-up was 14.9 months (IQR, 7.0–28.8). Esophageal perforation was identified in 20 (15.5%) patients, resulting in esophago-pleural fistula in nine, esophago-tracheal fistula in seven, broncho-esophageal fistula in two, and aorto-esophageal fistula in two patients. The median interval from IMRT to the occurrence of esophageal fistula was 4.4 months (IQR, 3.3–10.1). Patients with esophageal fistula had an inferior median overall survival (10.0 vs. 17.2 months, p = 0.0096). T4 (HR, 3.776; 95% CI, 1.383–10.308; p = 0.010) and esophageal stenosis (HR, 2.601; 95% CI, 1.053–6.428; p = 0.038) at baseline were the independent risk factors for esophageal fistula. The cumulative incidence of esophageal fistula was higher in patients with T4 (p = 0.018) and pre-treatment esophageal stenosis (p = 0.045). There was a trend toward better survival after esophageal fistula among patients receiving repair or stenting for the fistula than those only undergoing conservative treatments (median survival, 5.9 vs. 0.9 months, p = 0.058). CONCLUSIONS: T4 and esophageal stenosis at baseline independently increased the risk of esophageal fistula in ESCC treated by definitive CCRT with IMRT. There existed a trend toward improved survival after the fistula among patients receiving repair or stenting for esophageal perforation.
format Online
Article
Text
id pubmed-8121322
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-81213222021-05-24 Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma Pao, Tzu-Hui Chen, Ying-Yuan Chang, Wei-Lun Chang, Jeffrey Shu-Ming Chiang, Nai-Jung Lin, Chia-Ying Lai, Wu-Wei Tseng, Yau-Lin Yen, Yi-Ting Chung, Ta-Jung Lin, Forn-Chia PLoS One Research Article BACKGROUND: The literature regarding esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy (IMRT) for esophageal squamous cell carcinoma (ESCC) remains lacking. We aimed to investigate the risk factors of esophageal fistula among ESCC patients undergoing definitive concurrent chemoradiotherapy (CCRT) via IMRT technique. METHODS: A total of 129 consecutive ESCC patients receiving definitive CCRT with IMRT between 2008 and 2018 were reviewed. The cumulative incidence of esophageal fistula and survival of patients were estimated by the Kaplan–Meier method and compared between groups by the log-rank test. The risk factors of esophageal fistula were determined with multivariate Cox proportional hazards regression analysis. RESULTS: Median follow-up was 14.9 months (IQR, 7.0–28.8). Esophageal perforation was identified in 20 (15.5%) patients, resulting in esophago-pleural fistula in nine, esophago-tracheal fistula in seven, broncho-esophageal fistula in two, and aorto-esophageal fistula in two patients. The median interval from IMRT to the occurrence of esophageal fistula was 4.4 months (IQR, 3.3–10.1). Patients with esophageal fistula had an inferior median overall survival (10.0 vs. 17.2 months, p = 0.0096). T4 (HR, 3.776; 95% CI, 1.383–10.308; p = 0.010) and esophageal stenosis (HR, 2.601; 95% CI, 1.053–6.428; p = 0.038) at baseline were the independent risk factors for esophageal fistula. The cumulative incidence of esophageal fistula was higher in patients with T4 (p = 0.018) and pre-treatment esophageal stenosis (p = 0.045). There was a trend toward better survival after esophageal fistula among patients receiving repair or stenting for the fistula than those only undergoing conservative treatments (median survival, 5.9 vs. 0.9 months, p = 0.058). CONCLUSIONS: T4 and esophageal stenosis at baseline independently increased the risk of esophageal fistula in ESCC treated by definitive CCRT with IMRT. There existed a trend toward improved survival after the fistula among patients receiving repair or stenting for esophageal perforation. Public Library of Science 2021-05-14 /pmc/articles/PMC8121322/ /pubmed/33989365 http://dx.doi.org/10.1371/journal.pone.0251811 Text en © 2021 Pao et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Pao, Tzu-Hui
Chen, Ying-Yuan
Chang, Wei-Lun
Chang, Jeffrey Shu-Ming
Chiang, Nai-Jung
Lin, Chia-Ying
Lai, Wu-Wei
Tseng, Yau-Lin
Yen, Yi-Ting
Chung, Ta-Jung
Lin, Forn-Chia
Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma
title Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma
title_full Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma
title_fullStr Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma
title_full_unstemmed Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma
title_short Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma
title_sort esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121322/
https://www.ncbi.nlm.nih.gov/pubmed/33989365
http://dx.doi.org/10.1371/journal.pone.0251811
work_keys_str_mv AT paotzuhui esophagealfistulaafterdefinitiveconcurrentchemotherapyandintensitymodulatedradiotherapyforesophagealsquamouscellcarcinoma
AT chenyingyuan esophagealfistulaafterdefinitiveconcurrentchemotherapyandintensitymodulatedradiotherapyforesophagealsquamouscellcarcinoma
AT changweilun esophagealfistulaafterdefinitiveconcurrentchemotherapyandintensitymodulatedradiotherapyforesophagealsquamouscellcarcinoma
AT changjeffreyshuming esophagealfistulaafterdefinitiveconcurrentchemotherapyandintensitymodulatedradiotherapyforesophagealsquamouscellcarcinoma
AT chiangnaijung esophagealfistulaafterdefinitiveconcurrentchemotherapyandintensitymodulatedradiotherapyforesophagealsquamouscellcarcinoma
AT linchiaying esophagealfistulaafterdefinitiveconcurrentchemotherapyandintensitymodulatedradiotherapyforesophagealsquamouscellcarcinoma
AT laiwuwei esophagealfistulaafterdefinitiveconcurrentchemotherapyandintensitymodulatedradiotherapyforesophagealsquamouscellcarcinoma
AT tsengyaulin esophagealfistulaafterdefinitiveconcurrentchemotherapyandintensitymodulatedradiotherapyforesophagealsquamouscellcarcinoma
AT yenyiting esophagealfistulaafterdefinitiveconcurrentchemotherapyandintensitymodulatedradiotherapyforesophagealsquamouscellcarcinoma
AT chungtajung esophagealfistulaafterdefinitiveconcurrentchemotherapyandintensitymodulatedradiotherapyforesophagealsquamouscellcarcinoma
AT linfornchia esophagealfistulaafterdefinitiveconcurrentchemotherapyandintensitymodulatedradiotherapyforesophagealsquamouscellcarcinoma